Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc.
Agreement grants access to Synaffix patent portfolio related to metal-free click chemistry Technology to be used in Illumina's next-generation sequencing (NGS) products AMSTERDAM, Dec. 4, 2024 ...
SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped ...
SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic ...
During the meeting, Steve Barnard, PhD, Illumina’s CTO will provide new details about the company’s constellation mapped read technology. He will be joined by Niall Lennon, PhD, chair and CSO of Broad ...
San Diego gene sequencing giant Illumina is investing more in artificial intelligence to fuel the company’s growth strategy through a partnership with Nvidia. Nvidia — the Santa Clara tech company at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results